Your session is about to expire
← Back to Search
IVIG vs SCIG for CIDP
Study Summary
This trial will look at how body weight affects the effectiveness of IgG when given through IV or injection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not receiving IVIG for conditions other than CIDP.I am over 18 and have been diagnosed with CIDP.I have a weakened immune system.My liver and kidney functions are within normal ranges.I have diabetes.I currently have cancer.I have myasthenia gravis.My weekly dose for SCIG is between 0.2 and 0.4 mg/kg.I am over 18 and have been diagnosed with CIDP.My weekly dose for SCIG is between 0.2 and 0.4 mg/kg.I am over 18 and have been diagnosed with CIDP.
- Group 1: Intravenous immune globulin G
- Group 2: Subcutaneous immune globulin G
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What aims is this medical trial trying to achieve?
"The principal metric quantifying success of this clinical trial, measured over the course of 4 weeks, is the serum concentration of immunoglobulin G after intravenous infusion. Additionally, participants' fatigue intensity will be assessed via Rasch-built Fatigue Severity Scale (R-FSS), muscle strength and function through Medical Research Council's score system, and finally grip strength with a handheld Martin Vigorimeter."
Has the FDA authorized the use of Intravenous immune globulin G?
"Due to limited safety and efficacy data, Intravenous immune globulin G achieved a score of 1."
How many participants are currently involved in this research?
"Affirmative. According to the information hosted on clinicaltrials.gov, this medical trial is actively seeking applicants and was first posted on October 18th 2022. 20 participants are required from 1 centre with no recent updates since October 13th of the same year."
Is this experiment open to enrollment?
"Affirmative. The details on clinicaltrials.gov demonstrate that this investigation is actively recruiting participants, having first been posted to the website on October 18th 2022 and lastly updated on 13th of the same month. 20 people are needed at a single centre for enrolment in this study."
Am I eligible to become involved in this medical experiment?
"This medical research is looking for 20 individuals, aged 18 to 65, that have been diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy. Furthermore, it's necessary for potential participants to meet the following criteria: according to European Federation of Neurological sciences/Peripheral Nerve Society CIDP diagnostic standards they must be over 18 and their weekly dose conversion rate (1:1 IVIG converted into SCIG) must fall within 0.2-to-0.4 mg/kg."
Is this trial restricted to any particular age group?
"Candidates aged between 18 and 65 are eligible to participate in this study. There is a separate set of trials for those below the age of consent (4) as well as additional ones targeting an elderly population (34)."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Rutgers, The State University of New Jersey Clinical Research Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger